Miami, FLNCT07207408Now EnrollingIRB Ready

Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersinia Pestis Clinical Trial in Miami, FL

Access cutting-edge prevention of pneumonic plague resulting from aerosol exposure to yersinia pestis treatment through this clinical trial at a research site in Miami. Study-provided care at no cost to qualified participants.

Sponsored by Dynavax Technologies Corporation

Quick Self-Assessment

See if you qualify for this Miami location

Preparing your pre-screening questions…

Expert Care in Miami

Access prevention of pneumonic plague resulting from aerosol exposure to yersinia pestis specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related prevention of pneumonic plague resulting from aerosol exposure to yersinia pestis treatment provided free

Apply for This Miami Location

Check if you qualify for this prevention of pneumonic plague resulting from aerosol exposure to yersinia pestis clinical trial in Miami, FL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Miami

    Convenient for FL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Miami site if eligible
  4. 4Begin participation

About This Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersinia Pestis Study in Miami

This study will evaluate the immunogenicity, safety, and tolerability of rF1V-1018 vaccine

Sponsor: Dynavax Technologies Corporation

Who Can Participate

Inclusion Criteria

Adults 18 to 55 years of age
Healthy participants or participants with stable pre-existing medical conditions Pre-existing stable medical condition means a participant who: has full capacity of daily activity and no major medication modification within 3 months prior to Day 1; has not undergone surgical or minimally-invasive intervention or had any hospitalization/emergency room visit for the specific medical condition.
Able to comply with the protocol schedule and procedures
Able and willing to provide written informed consent
If female of child-bearing potential and heterosexually active, has practiced adequate contraception for at least 28 days prior to vaccination, has negative pregnancy tests just prior to vaccination, and has agreed to continue adequate contraception through three months following the final trial injection A premenopausal woman who has at least one of the following is considered not of childbearing potential:
Documented hysterectomy
Documented bilateral salpingectomy
Documented bilateral oophorectomy
Documented and current bilateral tubal ligation or occlusion

Exclusion Criteria

A history of plague disease or have previously received any plague vaccine
Active tuberculosis or other systemic infectious process
History of human immunodeficiency virus (HIV), hepatitis B (HBV) or hepatitis C (HCV) infection, or positive test for antibody to HIV, HBV, or HCV
History of autoimmune disorder
History of sensitivity to any component of trial vaccines
Body mass index ≥ 30 kg/m2
Has received the following prior to any trial injection: a) ≤ 14 days: i) Any licensed or authorized inactivated vaccines (including vaccines containing mRNA or CpG) b) ≤ 28 days: i) Any live vaccine ii) Any investigational medicinal agent c) ≤ 90 days: i) Chronic administration (defined as more than 14 consecutive days in total) of immunosuppressants or other immune-modifying drugs during the period starting 90 days prior to the first trial vaccine administration or planned administration during the trial period. (For corticosteroids, this will mean prednisone ≥20 mg/day, or equivalent). Inhaled, topical, and intraarticular steroids are allowed. ii) Granulocyte or granulocyte-macrophage colony stimulating factor iii) Immunoglobulins or any blood products (receipt of certain monoclonal antibodies may on a case-by-case basis be non-exclusionary if approved via consultation with Sponsor Medical Monitor) iv) Antisense oligonucleotides v) Drugs/investigational agents with very long half-lives (defined as ≥ 60 days) (eg, radioactive iodine, amiodarone, liraglutide, nirsevimab, teplizumab, evinacumab, and obinutuzumab) vi) Infusion of blood products d) At any time: DNA plasmids or other genetic therapy intended to integrate permanently into host cells
If female is pregnant (known before or established at the time of screening), breastfeeding, or planning breastfeeding or a pregnancy
Is undergoing chemotherapy or expected to receive chemotherapy during the trial period; has a diagnosis of cancer within the last 5 years other than squamous cell or basal cell carcinoma of the skin
History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with participation for the full duration of the trial, or is not in the best interest of the participant to participate, in the opinion of the treating investigator
Oral temperature ≥ 38°C (≥ 100.4°F) at the time of vaccine administration
History of acute myocardial infarction (AMI) or documented coronary artery disease (CAD) \-

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Miami?

Yes, this clinical trial (NCT07207408) has an active research site in Miami, FL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersinia Pestis Treatment Options in Miami, FL

If you're searching for prevention of pneumonic plague resulting from aerosol exposure to yersinia pestis treatment options in Miami, FL, this clinical trial (NCT07207408) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Miami research site is actively enrolling participants for this clinical trial. You'll receive care from experienced prevention of pneumonic plague resulting from aerosol exposure to yersinia pestis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all prevention of pneumonic plague resulting from aerosol exposure to yersinia pestis clinical trials near you to find additional studies recruiting in your area.

More Pulmonary Embolism Trials in Miami, FL

See all pulmonary embolism clinical trials recruiting in Miami — not just this study.

Browse Pulmonary Embolism Trials in Miami →

Browse More Trials by Condition

Pulmonary Embolism TrialsPrurigo Nodularis TrialsInterstitial Cystitis TrialsXeroderma Pigmentosum TrialsAll Conditions →

Ready to Join in Miami?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Miami, FL